Galidesivir hydrochloride
Based on 12 publication(s) in Google Scholar
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM.
For research use only. We do not sell to patients.
- Purity: 98.26%
- CAS No.: 222631-44-9
- Formula: C11H16ClN5O3
- Molecular Weight:301.73
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Galidesivir hydrochloride
More- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Biomed Pharmacother. 2025 Apr 28:187:118104. [Abstract]
- Antimicrob Agents Chemother. 2019 Feb 26;63(3):e02093-18. [Abstract]
- Microorganisms. 2021 Mar 31;9(4):734. [Abstract]
- Antiviral Res. 2017 Jun:142:63-67. [Abstract]
- Viruses. 2020 Jun 10;12(6):628. [Abstract]
- Virology. 2023 Aug:585:21-31. [Abstract]
- Exp Ther Med. 2016 Sep;12(3):1812-1816. [Abstract]
- J AOAC Int. 2024 Jun 13:qsae047. [Abstract]
- bioRxiv. 2025 Sep 22.
- bioRxiv. 2025 April 22.
- bioRxiv. 2025 January 29.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
RNA Polymerase |
Cellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination[1].
Galidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Galidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Syrian golden hamsters (hamsters infected with YF virus)[4]
-
Dosage:4 mg/kg of body weight
-
Administration:I.p.; twice daily for 7 days
-
Result:Significantly improved the survival of hamsters infected with YFV.
Chemical Information
-
CAS No. 222631-44-9
-
Appearance Solid
-
Molecular Weight 301.73
-
Formula C11H16ClN5O3
-
Color White to yellow
-
SMILES
O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O.Cl
-
Synonyms
BCX4430 hydrochloride; Immucillin-A hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Biomed Pharmacother
Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]2025 Apr 28:187:118104. PMID: 40300391 -
Antimicrob Agents Chemother
Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2'- C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection. [Abstract]2019 Feb 26;63(3):e02093-18. PMID: 30642926 -
Microorganisms
Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. [Abstract]2021 Mar 31;9(4):734. PMID: 33807492 -
Antiviral Res
Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. [Abstract]2017 Jun:142:63-67. PMID: 28336346 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
Virology
BCX4430 inhibits the replication of rabies virus by suppressing mTOR-dependent autophagy invitro. [Abstract]2023 Aug:585:21-31. PMID: 37267717 -
Exp Ther Med
Separation of cordycepin from Cordyceps militaris fermentation supernatant using preparative HPLC and evaluation of its antibacterial activity as an NAD+-dependent DNA ligase inhibitor. [Abstract]2016 Sep;12(3):1812-1816. PMID: 27588098 -
J AOAC Int
Green and Versatile High Throughput Microwell Oxidation-Based Spectrophotometric Methods for Determination of Galidesivir in Capsules. [Abstract]2024 Jun 13:qsae047. PMID: 38870529 -
-
-
Solvent & Solubility
DMSO : 105 mg/mL (347.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 41 mg/mL (135.88 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5.25 mg/mL (17.40 mM); Clear solution
This protocol yields a clear solution of ≥ 5.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (52.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5.25 mg/mL (17.40 mM); Clear solution
This protocol yields a clear solution of ≥ 5.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (52.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (331.42 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220-226. [Content Brief]
[2]. Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592. [Content Brief]
[3]. Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-405. [Content Brief]
[4]. Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58(11):6607-6614. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.3142 mL | 16.5711 mL | 33.1422 mL | 82.8555 mL |
| 5 mM | 0.6628 mL | 3.3142 mL | 6.6284 mL | 16.5711 mL | |
| 10 mM | 0.3314 mL | 1.6571 mL | 3.3142 mL | 8.2856 mL | |
| 15 mM | 0.2209 mL | 1.1047 mL | 2.2095 mL | 5.5237 mL | |
| 20 mM | 0.1657 mL | 0.8286 mL | 1.6571 mL | 4.1428 mL | |
| 25 mM | 0.1326 mL | 0.6628 mL | 1.3257 mL | 3.3142 mL | |
| 30 mM | 0.1105 mL | 0.5524 mL | 1.1047 mL | 2.7619 mL | |
| 40 mM | 0.0829 mL | 0.4143 mL | 0.8286 mL | 2.0714 mL | |
| 50 mM | 0.0663 mL | 0.3314 mL | 0.6628 mL | 1.6571 mL | |
| 60 mM | 0.0552 mL | 0.2762 mL | 0.5524 mL | 1.3809 mL | |
| 80 mM | 0.0414 mL | 0.2071 mL | 0.4143 mL | 1.0357 mL | |
| 100 mM | 0.0331 mL | 0.1657 mL | 0.3314 mL | 0.8286 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz